Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in
pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinicalstage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of its unique and industry leading NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.
Nxera
employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland), and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
Alliance Members
Territories
We offer a single entry point for our partners with orphan portfolios in ANZSEA, Canada, CEE, LATAM, MENAT, Cyprus, Greece, Israel, Japan and South Korea, Malta, Subcontinental Africa, Russia and CIS, and Switzerland.
Together we can achieve more.
With deep understanding of local healthcare systems, we can support our partners to expand their business throughout the complex WODA regions.
Contact us